Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Expert Rev Vaccines. 2015;14(8):1099-112. doi: 10.1586/14760584.2015.1059282. Epub 2015 Jun 22.
A decade after licensure of the human rotavirus vaccine (HRV), a wealth of evidence supports a reduction of rotavirus (RV) gastroenteritis-associated mortality and hospitalizations following HRV inclusion in national immunization programs. Nevertheless, the majority of real-world data has been generated in high- or middle-income settings. Clinical efficacy trials previously indicated RV vaccine performance may be lower in less-developed countries compared with wealthier counterparts. Using recently published data from Africa, we examine the effectiveness and impact of HRV in resource-deprived areas, exploring whether vaccine performance differs by socioeconomic setting and the potential underlying factors. HRV vaccine effectiveness in early adopting African countries has proven to be similar or even superior to the efficacy results observed in pre-licensure studies.
人轮状病毒疫苗（HRV）获得许可十年后，大量证据支持在国家免疫计划中纳入 HRV 以减少轮状病毒（RV）相关的肠胃炎死亡率和住院率。然而，大多数实际数据是在高收入或中等收入国家产生的。临床疗效试验此前表明，与较富裕国家相比，RV 疫苗在欠发达国家的表现可能较低。利用最近在非洲发表的数据，我们研究了 HRV 在资源匮乏地区的有效性和影响，探讨了疫苗的表现是否因社会经济环境的不同而有所差异，以及潜在的相关因素。在早期采用 HRV 的非洲国家，HRV 疫苗的有效性已被证明与许可前研究中观察到的疗效结果相似，甚至更优。
